Project HOPE, a global health education and humanitarian organization, is teaming up with leading companies and organizations from the pharmaceutical and healthcare industries, including AstraZeneca, to establish the China Alliance of Respiratory Diseases Prevention and Treatment (CARD) program. CARD aims to improve the lives of the more than 100 million people who suffer from respiratory diseases in China.
In China, asthma and COPD are the most common chronic respiratory diseases. Approximately 30 million Chinese patients suffer from asthma, which is also the most common chronic disease among children. The prevalence of pediatric asthma is 4% and the treatment rate is 86%, compared to the 1.78% prevalence rate of adult asthma and 39% treatment rate.
There are approximately 100 million Chinese with COPD, which account for 11.9% of deaths in China. Health officials fear that millions of people will die from COPD every year without more effective treatment and prevention methods.
Partnerships to Tackle Chronic Respiratory Diseases in China
